The FDA has approved efsitora, sold under the brand name Onswik, a once-weekly basal insulin for adults with type 2 diabetes, according to Eli Lilly's announcement reported by multiple outlets.
The drug is indicated as an adjunct to diet and exercise and is designed to deliver steady basal insulin over a week, according to MedPage Today.
STAT reported the approval gives patients an alternative to daily long-acting insulin injections.
According to the New York Post, the once-weekly treatment could reduce the number of injections by more than 300 per year compared with once-daily basal insulin, per Eli Lilly.
How each side covered it
Center
- MedPage Today reported the FDA approved Eli Lilly's once-weekly basal insulin efsitora, branded Onswik, for adults with type 2 diabetes.
- MedPage Today noted the drug is indicated as an adjunct to diet and exercise and delivers steady basal insulin.
- STAT described the approval as giving patients an alternative to daily long-acting insulin injections.
“The FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering patients an alternative to daily long-acting insulin injections.” — STAT
Right
- The New York Post emphasized the once-weekly treatment could cut injections by more than 300 per year compared with daily basal insulin, citing Eli Lilly.
“The once-weekly treatment could reduce the number of injections by more than 300 per year compared with once-daily basal insulin, Eli Lilly said.” — New York Post
Questions readers ask
What did the FDA approve?
The FDA approved efsitora, sold as Onswik, a once-weekly basal insulin made by Eli Lilly for adults with type 2 diabetes, according to MedPage Today and STAT.
How is this different from existing insulin treatments?
Efsitora is administered once a week rather than daily, offering patients an alternative to daily long-acting insulin injections, according to STAT.
How much could this reduce injections?
According to the New York Post, citing Eli Lilly, the once-weekly treatment could reduce the number of injections by more than 300 per year compared with once-daily basal insulin.
Who is the drugmaker behind Onswik?
Eli Lilly developed efsitora (Onswik) and announced the FDA approval, according to MedPage Today and STAT.
Sources · 3 outlet reports
- MedPage TodayCenterFDA Approves Efsitora Weekly Insulin for Type 2 Diabetes
- STATCenterSTAT+: Lilly wins approval for once-weekly insulin shot
- New York PostRight-leaningFDA approves Eli Lilly’s once-weekly insulin injection for type 2 diabetes